I-SPY2 TRIAL RPPA data for ganitumab arm (and control arm)

Pre-treatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify predictive biomarkers associated with response to the regimen of paclitaxel, an anti-type I IGF receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared to control therapy (paclitaxel followed by AC). This record contains protein/phosphoprotein data from pre-treatment laser capture microdissected (LCM) tumor biopsies for up to 162 key signaling proteins/phosphoproteins in cancer for 221 HER2-negative patients from 2 arms of the neoadjuvant I-SPY2 TRIAL (NCT01042379) for aggressive early stage breast cancer [119 Control; 102 Ganitumab]. This record also contains clinical data for these patients, including HR, and HER2 status, response (pCR or no pCR), and treatment arm. RPPA endpoints assayed are from hormone receptor (n=4), HER family (n=14), cell cycle/proliferation (n=20), immune (n=18), DNA repair deficiency (DDR; n=15), AKT/mTOR/PI3K (n=7), apoptosis/autophagy (n=10), IGF1R (n=6), TIE/ANG (n=4), growth/survival/metabolism (n=22) and RTK (n=19) and other pathways. For gene expresson data for these patients, see the GEO record/subseries GSE194040. Reverse phase protein array (RPPA) array run on isolates from pre-treatment breast cancer biopsy samples that were first LCM-enriched for epithelial cells. The sample characteristics and their values represent: HER2: the status of the HER2 gene. 1 = positive; 0 = negative. HR: the status of hormone (estrogen and progesterone) receptors. 1 = positive; 0 = negative. pCR: the status of a pathological complete response (pCR). 1 = complete response; 0 = failed complete response Arm: arm of the trial per patient, detailing treatment during taxol-phase of protocol: Paclitaxil (Control arm: HER2- subset); Paclitaxel + Ganitumab. All patients also received subsequent doxorubicin + cyclophosphamide. Arm (short name): abbreviated name of treatment arm in the trial per patient (n=2 arms) - Control, Ganitumab RPPA Array: Platform Array version. Key to convert from raw to normalized data.